All filters
Slidesets
Clinical Management of HIV-HBV and HIV-HCV Coinfection - Jürgen Rockstroh, MD (CH)
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2019
Slidesets
Clinical Characteristics and Prognostic Factors of Cryptococcal Meningitis Among HIV-Infected Patients - Yinzhong Shen, MD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2019
Slidesets
Clinical Management of HIV-HBV and HIV-HCV Coinfection - Jürgen Rockstroh, MD (EN)
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2019
Slidesets
Novel Biomarkers for Chronic Hepatitis B - Xiaonan Zhang, PhD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2019
Slidesets
Oxazolidinones for TB: Current Status and Future Prospects - Lawrence Geiter
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Evaluating Hepatotoxicity of Bedaquiline Treatment in Multi-Drug Resistant Tuberculosis Patients - Lénaïg Tanneau
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Relationship Between Plasma and Intracellular Concentrations of Bedaquiline and its M2 Metabolite in South African Patients with Drug-Resistant TB - Precious Ngwalero
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Pharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TB - Ahmed Aliyu Abulfathi
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Co-Administration of Pretomanid with Rifampin or Rifabutin Among Patients with Pulmonary TB: Interim PK Results from “Assessing Pretomanid for Tuberculosis” (APT) Trial - Elisa Ignatius
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Exposures to First-Line Drugs in African and Indian Children with Drug-Susceptible Tuberculosis using Novel Fixed-Dose-Combination Tablets at WHO Dosing Recommendation in the SHINE Trial - Chishala Chabala
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Ethionamide Population Pharmacokinetic Model and Monte Carlo Simulation in Patients with Multidrug-Resistant Tuberculosis - Charles Peloquin
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Can Longitudinal PKPD Biomarkers be used to Forecast Treatment Outcome Instead of M2 Conversion? A Population Pharmacokinetic-Pharmacodynamic Analysis in Drug Sensitive Pulmonary Tuberculosis - Frank Kloprogge
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Pharmacokinetic-Pharmacodynamic Analysis in TB Drug Development and the Role of the WHO - Ernesto Jaramillo
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
PK-PD of Isoniazid Given at Different Doses Among Patients with MDR-TB with INH Resistance Mediated by inhA Mutations: Modeling Results from ACTG A5312 - Kamunkhwala Gausi
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment Analysis - Charles Peloquin
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Drug Effect of Clofazimine on Persistent Mycobacteria Explain an Unexpected Increase of Bacterial Load in Patients - Alan Faraj
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Levofloxacin Target Attainment Analysis in MDR-TB Patients: Time is Ripe for Proactive TDM - Mathieu Bolhuis
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Hepatitis C Elimination: Is It Possible?- Andrea Cox, MD
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Slidesets
Starting HAART in 2019: When and How- Pedro Cahn, MD, PhD
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Slidesets
Challenges with the Implementation of PrEP- Kenneth Mayer, MD
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Slidesets
The Puerto Rican Experience - Discussion- Vivian Tamayo
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Slidesets
PEP After Sexual Exposures- Mauro Schechter, MD, PhD
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Slidesets
New ARVs/New Strategies- Pablo Tebas, MD
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019
Slidesets
Local Situation in Puerto Rico: Epidemiology and Treatment Options- Jorge Santana-Bagur, MD
Presented at:
Puerto Rico Meeting on Hepatitis & HIV 2019